K-V Pharmaceutical (KV-A) Up, Watson Pharmaceuticals (WPI) Down on FDA Panel Comments Over Columbia Labs’ (CRBX) on Preterm Birth Gel
Tweet
Share
E-mail
Shares of K-V Pharmaceutical (NYSE: KV-A) closed up 8.81 percent to $2.10 after spiking as high as $2.28 on news that the FDA panel declared Columbia Labs’ (Nasdaq: CRBX) data on preterm birth gel wasn’t sufficient.
Shares of CBRX have been halted since the opening bell on anticipation for the results, while on the other side of the trade shares of Watson Pharmaceuticals (NYSE: WPI) closed down 3.5 percent.
The panel voted 13 to 4 in favor of not supporting the preterm birth gel.
Shares of CBRX have been halted since the opening bell on anticipation for the results, while on the other side of the trade shares of Watson Pharmaceuticals (NYSE: WPI) closed down 3.5 percent.
The panel voted 13 to 4 in favor of not supporting the preterm birth gel.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic hires Google chip veteran as it pushed into hardware - Bloomberg
- FTC files amicus brief challenging Amgen's Enbrel patent acquisition
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
Create E-mail Alert Related Categories
Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
